These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 18425129)

  • 1. Mast cell activators: a new class of highly effective vaccine adjuvants.
    McLachlan JB; Shelburne CP; Hart JP; Pizzo SV; Goyal R; Brooking-Dixon R; Staats HF; Abraham SN
    Nat Med; 2008 May; 14(5):536-41. PubMed ID: 18425129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
    Bento D; Staats HF; Gonçalves T; Borges O
    Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen.
    McGowen AL; Hale LP; Shelburne CP; Abraham SN; Staats HF
    Vaccine; 2009 Jun; 27(27):3544-52. PubMed ID: 19464533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines.
    Disis ML; Bernhard H; Shiota FM; Hand SL; Gralow JR; Huseby ES; Gillis S; Cheever MA
    Blood; 1996 Jul; 88(1):202-10. PubMed ID: 8704175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant.
    Park YS; Lee JH; Hung CF; Wu TC; Kim TW
    Infect Immun; 2008 May; 76(5):1952-9. PubMed ID: 18285494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques.
    Egan MA; Chong SY; Hagen M; Megati S; Schadeck EB; Piacente P; Ma BJ; Montefiori DC; Haynes BF; Israel ZR; Eldridge JH; Staats HF
    Vaccine; 2004 Sep; 22(27-28):3774-88. PubMed ID: 15315859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities.
    Sloat BR; Cui Z
    Pharm Res; 2006 Jun; 23(6):1217-26. PubMed ID: 16718616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A modified cholera holotoxin CT-E29H enhances systemic and mucosal immune responses to recombinant Norwalk virus-virus like particle vaccine.
    Periwal SB; Kourie KR; Ramachandaran N; Blakeney SJ; DeBruin S; Zhu D; Zamb TJ; Smith L; Udem S; Eldridge JH; Shroff KE; Reilly PA
    Vaccine; 2003 Jan; 21(5-6):376-85. PubMed ID: 12531635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge.
    Bielinska AU; Janczak KW; Landers JJ; Makidon P; Sower LE; Peterson JW; Baker JR
    Infect Immun; 2007 Aug; 75(8):4020-9. PubMed ID: 17502384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine.
    Klinman DM; Xie H; Ivins BE
    Ann N Y Acad Sci; 2006 Oct; 1082():137-50. PubMed ID: 17145935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen.
    Boyaka PN; Tafaro A; Fischer R; Leppla SH; Fujihashi K; McGhee JR
    J Immunol; 2003 Jun; 170(11):5636-43. PubMed ID: 12759444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unimpaired Responses to Vaccination With Protein Antigen Plus Adjuvant in Mice With Kit-Independent Mast Cell Deficiency.
    Schubert N; Lisenko K; Auerbach C; Weitzmann A; Ghouse SM; Muhandes L; Haase C; Häring T; Schulze L; Voehringer D; Gunzer F; Müller W; Feyerabend TB; Rodewald HR; Dudeck A; Roers A
    Front Immunol; 2018; 9():1870. PubMed ID: 30210490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of anthrax toxins in dissemination, disease progression, and induction of protective adaptive immunity in the mouse aerosol challenge model.
    Loving CL; Khurana T; Osorio M; Lee GM; Kelly VK; Stibitz S; Merkel TJ
    Infect Immun; 2009 Jan; 77(1):255-65. PubMed ID: 18955474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
    Wimer-Mackin S; Hinchcliffe M; Petrie CR; Warwood SJ; Tino WT; Williams MS; Stenz JP; Cheff A; Richardson C
    Vaccine; 2006 May; 24(18):3953-63. PubMed ID: 16530302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sublingual targeting of STING with 3'3'-cGAMP promotes systemic and mucosal immunity against anthrax toxins.
    Martin TL; Jee J; Kim E; Steiner HE; Cormet-Boyaka E; Boyaka PN
    Vaccine; 2017 Apr; 35(18):2511-2519. PubMed ID: 28343781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for adjuvanticity of anthrax edema toxin.
    Quesnel-Hellmann A; Cleret A; Vidal DR; Tournier JN
    Vaccine; 2006 Feb; 24(6):699-702. PubMed ID: 16168529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens.
    Sloat BR; Shaker DS; Le UM; Cui Z
    FEMS Immunol Med Microbiol; 2008 Mar; 52(2):169-79. PubMed ID: 18194342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys.
    Kachura MA; Hickle C; Kell SA; Sathe A; Calacsan C; Kiwan R; Hall B; Milley R; Ott G; Coffman RL; Kanzler H; Campbell JD
    J Immunol; 2016 Jan; 196(1):284-97. PubMed ID: 26608924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection.
    Lindqvist M; Persson J; Thörn K; Harandi AM
    J Immunol; 2009 May; 182(10):6435-43. PubMed ID: 19414797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mast cell activator compound 48/40 is not an effective adjuvant for UV-attenuated Toxoplasma gondii vaccine.
    Li X; Chen S; Huang S; Lu F
    Parasitol Res; 2017 Aug; 116(8):2347-2353. PubMed ID: 28573462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.